Novo Nordisk
NVO
1,529 hedge funds and large institutions have $23B invested in Novo Nordisk in 2025 Q1 according to their latest regulatory filings, with 140 funds opening new positions, 627 increasing their positions, 560 reducing their positions, and 247 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 627 | Existing positions reduced: 560
0.4% less ownership
Funds ownership: 9.97% → 9.57% (-0.4%)
8% less funds holding
Funds holding: 1,664 → 1,529 (-135)
22% less funds holding in top 10
Funds holding in top 10: 32 → 25 (-7)
24% less capital invested
Capital invested by funds: $30.2B → $23B (-$7.2B)
26% less call options, than puts
Call options by funds: $987M | Put options by funds: $1.34B
43% less first-time investments, than exits
New positions opened: 140 | Existing positions closed: 247
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$317M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$228M |
| 3 |
ClearBridge Investments
New York
|
+$194M |
| 4 |
Amundi
Paris,
France
|
+$134M |
| 5 |
Two Sigma Investments
New York
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$1.06B |
| 2 |
Polen Capital Management
Boca Raton,
Florida
|
-$446M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$350M |
| 4 |
Renaissance Technologies
New York
|
-$123M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$94.4M |
NVO Hedge Fund Activity: Q1 2025 in Review
1,529 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2025, worth a combined $23B — down 24% from $30.2B a quarter earlier.
Sellers outnumbered buyers: 247 funds closed out of NVO and 140 opened new positions — a net loss of 107 holders — while 560 trimmed existing stakes and 627 added.
The largest buyer was Two Sigma Advisers, adding an estimated $317M. The largest seller was GQG Partners, cutting an estimated $1.06B.
- 1,529 institutional investors held Novo Nordisk (NVO) as of Q1 2025, down from 1,664 in Q4 2024.
- Funds reported $23B of Novo Nordisk stock for Q1 2025, down 24% quarter-over-quarter.
- 140 funds opened new Novo Nordisk positions in Q1 2025 and 247 closed out, a net change of -107 holders.
- The largest Novo Nordisk buyer in Q1 2025 was Two Sigma Advisers, an estimated $317M added.
- The largest Novo Nordisk seller in Q1 2025 was GQG Partners, an estimated $1.06B sold.
Based on aggregated 13F filings for Q1 2025.